ClinicalTrials.gg

Program

empagliflozin

Also written as “BI 10773”, “Empagliflozin” and “BI10773”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Heart Failure · Diabetes Mellitus, Type 1 · Renal Insufficiency, Chronic · Diabetes Mellitus, Lipoatrophic, led by 15 companies.

Furthest: phase 4, since Oct 27, 2015124 company-led studies, 8 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim992 open or runningphase 4since Oct 27, 2015Nov 14, 2007Dec 11, 2026phase 1 · NCT07845630
ADIUM40 open or runningno phasesince Mar 9, 2026Mar 9, 2026none ahead
Getz Pharma41 open or runningphase 4since Nov 27, 2020Nov 27, 2020Dec 31, 2026phase 4 · NCT05164263
Gedeon Richter Plc.30 open or runningphase 1since Dec 10, 2024Dec 10, 2024none ahead
Chong Kun Dang Pharmaceutical21 open or runningphase 4since Jan 15, 2026Aug 1, 2016Aug 2027phase 4 · NCT07365358
Dong Wha Pharmaceutical20 open or runningphase 1since Apr 10, 2023Apr 10, 2023none ahead
Kobe University20 open or runningphase 3since Jul 10, 2019Jul 10, 2019none ahead
Celltrion11 open or runningphase 3since Jun 30, 2025Jun 30, 2025Dec 2026phase 3 · NCT07093476
Dong-A ST10 open or runningphase 1since Dec 5, 2018Dec 5, 2018none ahead
Genuine Research Center, Egypt10 open or runningphase 1since Nov 16, 2021Nov 16, 2021none ahead
hyundai-pharm11 open or runningphase 1since Jul 4, 2024Jul 4, 2024none ahead
Intarcia Therapeutics10 open or runningphase 3since Feb 9, 2017Feb 9, 2017none ahead
Nabiqasim Industries (Pvt)11 open or runningphase 4since Feb 19, 2025Feb 19, 2025none ahead
pharma-nueva11 open or runningphase 1since Mar 6, 2024Mar 6, 2024none ahead
Profil Institut für Stoffwechselforschung10 open or runningphase 4since Aug 14, 2017Aug 14, 2017none ahead

Also a collaborator on its studies: Eli Lilly.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 44 studies since Oct 27, 2014.

  1. Dec 10, 2024Gedeon Richter Plc.'s first study: phase 1 study in Diabetes Mellitus, Type 2New to Gedeon Richter Plc.Gedeon Richter Plc. · NCT06766500 · 64 enrolled · Russian Federation
  2. Jan 20, 2025Phase 1 study in Diabetes Mellitus, Type 2Gedeon Richter Plc. · NCT06792968 · 64 enrolled · Russian Federation
  3. Feb 7, 2025Phase 1 study in Diabetes Mellitus, Type 2Gedeon Richter Plc. · NCT06823856 · 64 enrolled · Russian Federation
  4. Feb 19, 2025Nabiqasim Industries (Pvt)'s first study: phase 4 study in Diabetes MellitusNew to Nabiqasim Industries (Pvt)Nabiqasim Industries (Pvt) · NCT06862739 · 800 planned · Pakistan
  5. Apr 11, 2025Phase 2 study in Renal Insufficiency, ChronicBoehringer Ingelheim · NCT06926660 · 492 enrolled · United States, Argentina, Australia and more
  6. Apr 30, 2025Phase 1 study in HealthyBoehringer Ingelheim · NCT06962826 · 14 enrolled · Germany
  7. Jun 17, 2025Phase 1 study in HealthyBoehringer Ingelheim · NCT07035457 · 15 enrolled · Germany
  8. Jun 30, 2025Celltrion's first study: phase 3 study in Diabetes Mellitus, Type 2New to CelltrionCelltrion · NCT07093476 · 171 planned · South Korea
  9. Aug 5, 2025Phase 3 study in Renal Insufficiency, ChronicBoehringer Ingelheim · NCT07107945 · 135 enrolled · United States, Argentina, Australia and more
  10. Aug 19, 2025Phase 1 study in HealthyBoehringer Ingelheim · NCT07133399 · 32 enrolled · Germany
  11. Jan 15, 2026Phase 4 study in Diabetes Mellitus, Type 2Chong Kun Dang Pharmaceutical · NCT07365358 · 200 planned · South Korea
  12. Mar 9, 2026ADIUM's first study: no phase study in BioequivalanceNew to ADIUMADIUM · NCT07479108 · 32 enrolled · Mexico
  13. Jun 3, 20263 no phase studies in Bioequivalence Study in Healthy SubjectsADIUM · NCT07633054, NCT07633041, NCT07633028
  14. Sep 23, 2026Phase 1 study in HealthyBoehringer Ingelheim · NCT07845630 · 36 planned · Germany

Ahead

  1. Dec 2026Primary completion: phase 3 study in Diabetes Mellitus, Type 2Celltrion · NCT07093476
  2. Dec 11, 2026Primary completion: phase 1 study in HealthyBoehringer Ingelheim · NCT07845630
  3. Dec 31, 2026Primary completion: phase 4 study in Diabetes Mellitus, Type 2Getz Pharma · NCT05164263
  4. Apr 16, 2027Primary completion: phase 3 study in Renal Insufficiency, ChronicBoehringer Ingelheim · NCT07107945

TargetBeta

SLC5A2 →read by rule
“An orally available competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2; SLC5A2) with antihyperglycemic activity”NCIt, by rule
“Sodium/glucose cotransporter 2 inhibitor”ChEMBL 37, by rule

Other programs on SLC5A2

ProgramCompanyFurthest phaseStudies
dapagliflozinAstraZenecaphase 4133
ertugliflozinruleMerckphase 422
EnavogliflozinruleDaewoong Pharmaceuticalphase 325
vicadrostatBoehringer Ingelheimphase 316
Empagliflozin/LinagliptinruleHumanis Saglık Anonim Sirketiphase 12

Studies

The newest 60 of 124 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07845630Healthy · Germany1RecruitingBoehringer IngelheimDec 11, 202636
NCT07633054Bioequivalence Study in Healthy Subjects · Mexico–CompletedADIUMNov 24, 202542
NCT07633041Bioequivalence Study in Healthy Subjects · Mexico–CompletedADIUMApr 4, 202542
NCT07633028Bioequivalence Study in Healthy Subjects · Mexico–CompletedADIUMApr 8, 202542
NCT07479108Bioequivalance · Mexico–CompletedADIUMDec 11, 202432
NCT07365358Diabetes Mellitus, Type 2 · South Korea4Not yet recruitingChong Kun Dang PharmaceuticalAug 2027200
NCT07133399Healthy · Germany1CompletedBoehringer IngelheimOct 22, 202532
NCT07107945Renal Insufficiency, Chronic · United States, Argentina, Australia and more3Active, not recruitingBoehringer IngelheimApr 16, 2027135
NCT07093476Diabetes Mellitus, Type 2 · South Korea3RecruitingCelltrionDec 2026171
NCT07035457Healthy · Germany1CompletedBoehringer IngelheimAug 7, 202515
NCT06962826Healthy · Germany1CompletedBoehringer IngelheimJun 26, 202514
NCT06926660Renal Insufficiency, Chronic · United States, Argentina, Australia and more2CompletedBoehringer IngelheimAug 14, 2026492
NCT06862739Diabetes Mellitus · Pakistan4RecruitingNabiqasim Industries (Pvt)Apr 30, 2026800
NCT06823856Diabetes Mellitus, Type 2 · Russian Federation1CompletedGedeon Richter Plc.May 21, 202564
NCT06792968Diabetes Mellitus, Type 2 · Russian Federation1CompletedGedeon Richter Plc.Apr 6, 202564
NCT06766500Diabetes Mellitus, Type 2 · Russian Federation1CompletedGedeon Richter Plc.Feb 28, 202564
NCT06578676Diabetes Mellitus, Type 2 · Korea, Republic of1Recruitinghyundai-pharmSep 2, 202456
NCT06308679Healthy Vollunteer1Not yet recruitingpharma-nuevaMay 31, 202428
NCT05823883DW6014 · Korea, Republic of1UNKNOWNDong Wha PharmaceuticalJul 202330
NCT05823870Healthy Subjects · Korea, Republic of1CompletedDong Wha PharmaceuticalMar 6, 202332
NCT05359432Diabetes Mellitus, Type 2 · Pakistan4CompletedGetz PharmaAug 10, 2021120
NCT05182840Renal Insufficiency, Chronic · United States, Argentina, Australia and more2CompletedBoehringer IngelheimJun 19, 2023714
NCT05164263Diabetes Mellitus, Type 2 · Afghanistan, Kenya, Nigeria and more4RecruitingGetz PharmaDec 31, 20262,000
NCT05132023Healthy · Egypt1CompletedGenuine Research Center, EgyptApr 2, 201926
NCT05083949Healthy · Brazil1CompletedBoehringer IngelheimAug 6, 202132
NCT04976283Diabetes Mellitus, Type 2 · Pakistan4UNKNOWNGetz PharmaMay 15, 2023123
NCT04665284Diabetes Mellitus, Type 2 · Pakistan4CompletedGetz PharmaSep 15, 2020244
NCT04531462Diabetes Mellitus, Type 2 · Japan4CompletedBoehringer IngelheimAug 19, 2022129
NCT04509674Myocardial Infarction · United States, Argentina, Australia and more3CompletedBoehringer IngelheimNov 5, 20236,522
NCT04233801Diabetes Mellitus, Type 2 · China3CompletedBoehringer IngelheimMar 3, 2022219
NCT04221152Diabetes Mellitus, Insulin-Resistant, with Acanthosis Nigricans · Japan3UNKNOWNKobe UniversityFeb 1, 20228
NCT04157751Heart Failure · United States, Belgium, Canada and more3CompletedBoehringer IngelheimMay 28, 2021530
NCT04018365Diabetes Mellitus, Insulin-Resistant, with Acanthosis Nigricans · Japan3UNKNOWNKobe UniversityJul 31, 20218
NCT03766724Type2 Diabetes · Korea, Republic of1CompletedDong-A STJan 18, 201942
NCT03629054Healthy · Germany1CompletedBoehringer IngelheimNov 5, 201830
NCT03594110Renal Insufficiency, Chronic · United States, Canada, China and more3CompletedBoehringer IngelheimJul 5, 20226,609
NCT03448419Heart Failure · United States, Australia, Canada and more3CompletedBoehringer IngelheimSep 30, 2019312
NCT03448406Heart Failure · United States, Australia, Canada and more3CompletedBoehringer IngelheimOct 4, 2019315
NCT03429543Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more3CompletedBoehringer IngelheimOct 19, 2022175
NCT03332212Heart Failure · United Kingdom3CompletedBoehringer IngelheimMay 21, 202072
NCT03259490Healthy · Germany1CompletedBoehringer IngelheimNov 13, 201730
NCT03254849Diabetes Mellitus, Type 2 · Germany4CompletedProfil Institut für StoffwechselforschungApr 20, 202075
NCT03057977Heart Failure · United States, Argentina, Australia and more3CompletedBoehringer IngelheimMay 1, 20203,730
NCT03057951Heart Failure · United States, Argentina, Australia and more3CompletedBoehringer IngelheimApr 26, 20215,988
NCT03060980Diabetes Mellitus, Type 2 · United States, Canada3TerminatedIntarcia TherapeuticsJan 26, 2018245
NCT02854748Diabetes Mellitus, Type 2 · Korea, Republic of1UNKNOWNChong Kun Dang PharmaceuticalSep 201630
NCT02821910Healthy · Germany1CompletedBoehringer IngelheimOct 1, 201650
NCT02815644Healthy · Japan1CompletedBoehringer IngelheimOct 5, 201622
NCT02782624Healthy · Germany1CompletedBoehringer IngelheimNov 200916
NCT02758171Healthy · Germany1CompletedBoehringer IngelheimJul 29, 201656
NCT02702011Diabetes Mellitus, Type 1 · Japan2CompletedBoehringer IngelheimSep 5, 201648
NCT02632747Diabetes Mellitus, Type 1 · Canada2CompletedBoehringer IngelheimDec 19, 201731
NCT02589639Diabetes Mellitus, Type 2 · Japan4CompletedBoehringer IngelheimApr 18, 2017269
NCT02589626Diabetes Mellitus, Type 2 · Japan4CompletedBoehringer IngelheimJun 2, 201765
NCT02580591Diabetes Mellitus, Type 1 · United States, Australia, Canada and more3CompletedBoehringer IngelheimSep 12, 2017977
NCT02577315Healthy · Russian Federation1CompletedBoehringer IngelheimOct 201525
NCT02489968Diabetes Mellitus, Type 2 · Japan3CompletedBoehringer IngelheimNov 18, 2016880
NCT02453555Diabetes Mellitus, Type 2 · Japan3CompletedBoehringer IngelheimAug 26, 2016275
NCT02414958Diabetes Mellitus, Type 1 · United States, Australia, Austria and more3CompletedBoehringer IngelheimApr 20, 2017730
NCT02276365Healthy1CompletedBoehringer IngelheimJul 200920

How it is read

Names in the registry

  • “BI 10773”, 71 entries
  • “Empagliflozin”, 53 entries
  • “BI10773”, 7 entries
  • “Empagliflozin/Metformin”, 4 entries
  • “Empagliflozin + Linagliptin”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.